Here we highlight RBBP9, a metabolic serine hydrolase23 also shown to be crucial for pancreatic cancer cell survival, yet non-essential in several cell types and mice, as an attractive druggable candidate for FA-HNSCC treatment. This evidence concerns the gene RBBP9 and Friedreich ataxia.